LexaGene Holdings Inc. (OTCQB: LXXGF) (TSX-V:LXG) has appointed Joseph Caruso to the company’s board of directors as it looks to leverage his expertise and experience in bringing to market new medical devices. Caruso joins the company with vast experience at a pivotal time when the biotechnology firm is aggressively developing instrumentation products for pathogen detection.
Mr. Caruso Appointment
Mr. Caruso has previously served as the CEO and chairman of Palomar Medical Technology Inc. and in the process oversaw the launch of dozens of devices. He joins the biotechnology company with extensive executive, management, operational, regulatory and research and development experience. He is currently a member of the board of Endocellutions Inc.
LexaGene Holdings Inc. (OTCQB: LXXGF) (TSX-V:LXG) is putting the finishing touches to a number of products that it hopes will allow it to expand its footprint into multiple multi-billion dollar markets.
“As such, Mr. Caruso’s expertise and knowledge of developing new-to-the-market medical devices and moving novel technology into commercialization will serve us well as we come closer to the commercial launch of our products,” said Dr. Jack Regan, LexaGene’s CEO.
The appointment of Mr. Caruso comes just days after Lexagene confirmed that its pathogen detecting instrument is now capable of generating data as well as identifying the likes of E.coli and Staph bacteria. The technology seeks to make it easy for healthcare providers and food safety officers to detect pathogens with ease.
According to the Chief Executive Officer, generation of data marks a significant milestone for the company as it moves to pursue opportunities while combating foodborne illnesses. Focus now shifts towards optimizing the performance of the equipment while trying to equip it with reagents for detecting more diseases such as Salmonella and Listeria.
In addition to using the technology to detect pathogens in food items, Lexagene expects the technology to be of great help in helping doctors diagnose patients. Healthcare providers will in future not have to send samples far away and wait for days to get results. The company’s pathogen detection system will make it easy for healthcare providers to detect the presence of antibiotic resistance bacteria instantaneously.
LexaGene Holdings Inc. (OTCQB: LXXGF) (TSX-V:LXG) has also inked a string of strategic collaborations as it looks to accelerate the development and adoption of the pathogen detection products. First on the list is, a collaborative agreement with Texas A&M which is to furnish it with canine urine samples for testing using the LX6 prototype. According to the CEO, the samples will go a long way in refining the company’s assets as well as optimizing the LX6 prototype.
The biotechnology company has also entered into a collaboration agreement with Ethos Veterinary Health. The partnership allows the company to gain access to canine urine samples for testing using the LX6 prototype for more effective, rapid and on-site pathogen detection.
The company has also inked a partnership with the Stanford University School of Medicine. The agreement paves the way for the integration of a targeted sequencing technology developed by Professor Henlee Ji with the company’s Microfluidic instrument.
RESAAS Signs Joint Venture With San Francisco Title Technology Company to Tokenize every Property in the United States, backed by Investment Bank US Capital Global to Raise Up To $7 million USD
BREAKING NEWS UPDATE: July 31, 2018 – RESAAS Services Inc. (TSX.V: RSS, OTCQX: RSASF) RESAAS Signs Joint Venture With San Francisco Title...